Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
With a market cap of 952.5B, Eli Lilly(LLY) trades at $1,011.50. The stock has a price-to-earnings ratio of 44.58 and currently yields dividends of 58.6%.
On 2026-02-21, Eli Lilly(LLY) stock moved within a range of $1,002.46 to $1,028.12. With shares now at $1,011.50, the stock is trading +0.9% above its intraday low and -1.6% below the session's peak.
Trading volume for Eli Lilly(LLY) stock has reached 3.25M, versus its average volume of 3.24M.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.
LLY News
But it's good news for Eli Lilly, too. Novo Nordisk (NVO 2.13%) has struggled over the past year, and the company recently hit another setback when it reported...
Barclays Bank (BCS) has initiated coverage of U.S. large-cap pharmaceutical companies with four recommendations that the bank says are immediate buys. Analyst...
Eli Lilly’s (LLY) stock moved slightly higher after the pharmaceutical giant reported making progress with a new treatment for Crohn’s Disease. Data from a tri...
Analyst ratings
79%
of 33 ratingsMore LLY News
Eli Lilly and Co. (NYSE:LLY) on Thursday released promising long-term data regarding its treatment for Crohn’s disease. This news comes as the company reported...
Key Points Eli Lilly makes the best-performing GLP-1 drugs on the market today. The company faces intense competition and has a relatively short window of opp...
Eli Lilly (NYSE: LLY) just delivered 45% revenue growth and guided toward $83 billion in 2026 sales. With blockbuster obesity drugs, multiple growth catalysts,...
Barclays initiated coverage of Eli Lilly (LLY) with an Overweight rating and $1,350 price target The firm sees GLP-1 weight loss treatments as a “durable struct...
New long-term data from Eli Lilly (LLY) and Company showed Omvoh delivered durable efficacy through three years in adults with moderately to severely active Cro...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The RENEW-Op-1 study, officially titled “A Phase 2, Randomized, Double-Blind,...
Ozempic's rival is generating blockbuster revenue and gaining market share. Everyone has been talking about Ozempic in recent years. You may have seen the name...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.